Compare Inovio Pharmaceuticals Inc (INO) vs Intuitive Surgical, Inc. (ISRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Intuitive Surgical, Inc. — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while Intuitive Surgical, Inc. trades at $424 (market cap $146.76B). The key difference: Intuitive Surgical, Inc. is far larger — about 1308.1× Inovio Pharmaceuticals Inc's market cap, and Intuitive Surgical, Inc. is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Intuitive Surgical, Inc. for 84 Days on average.
| INO | ISRG | |
|---|---|---|
Market Cap | $112.19M | $146.76B |
Volume | 3,201,278 | 2,529,814 |
Sector | Health | Health |
52-Week High | $2.65 | $592.85 |
52-Week Low | $0.66 | $332.02 |
Typical Hold Time | 43 Days | 84 Days |
Enterprise Value | $83.51M | $141.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.15, down 0.43% on the day, with a bearish technical signal from moving averages and oscillators. The company shows consistent quarterly earnings beats but operates at significant losses with a -130,000% net income margin and negative cash flow. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with analyst consensus leaning bullish at a $2.75 price target.
The investment case hinges on FDA approval of INO-3107, offering substantial upside from current levels. However, persistent cash burn, minimal revenue, and high valuation multiples relative to sales pose significant risks. Investors face binary outcomes driven by regulatory decisions and commercialization execution.
Intuitive Surgical (ISRG) trades at $423.96, up 2.28% with strong bullish momentum. The stock shows robust fundamentals with 2025 revenue reaching $10.06B and net income of $2.86B, maintaining 28.45% net margins. Recent quarters consistently beat EPS estimates, while technical indicators signal bullish moving averages. Analyst consensus remains strongly positive with 70% buy ratings and $480.78 price target, representing 13% upside potential.
ISRG's leadership in robotic surgery and expanding international presence in India and Japan provide growth catalysts, though China weakness and competitive pressures present risks. The stock's premium valuation (P/E 47.64) reflects high growth expectations, requiring continued execution. Current levels near resistance at $427 may test near-term momentum ahead of Q3 earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →
